SCPH
Price
$2.50
Change
-$0.09 (-3.46%)
Updated
Apr 24, 02:48 PM (EDT)
Capitalization
131.24M
26 days until earnings call
THTX
Price
$2.76
Change
+$0.06 (+2.22%)
Updated
Apr 24, 02:51 PM (EDT)
Capitalization
125.72M
Ad is loading...

SCPH vs THTX

Header iconSCPH vs THTX Comparison
Open Charts SCPH vs THTXBanner chart's image
scPharmaceuticals
Price$2.50
Change-$0.09 (-3.46%)
Volume$500
Capitalization131.24M
Theratechnologies
Price$2.76
Change+$0.06 (+2.22%)
Volume$100
Capitalization125.72M
SCPH vs THTX Comparison Chart
Loading...
SCPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
THTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SCPH vs. THTX commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SCPH is a Hold and THTX is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (SCPH: $2.59 vs. THTX: $2.69)
Brand notoriety: SCPH and THTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SCPH: 36% vs. THTX: 24%
Market capitalization -- SCPH: $131.24M vs. THTX: $125.72M
SCPH [@Biotechnology] is valued at $131.24M. THTX’s [@Biotechnology] market capitalization is $125.72M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SCPH’s FA Score shows that 0 FA rating(s) are green whileTHTX’s FA Score has 1 green FA rating(s).

  • SCPH’s FA Score: 0 green, 5 red.
  • THTX’s FA Score: 1 green, 4 red.
According to our system of comparison, THTX is a better buy in the long-term than SCPH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SCPH’s TA Score shows that 5 TA indicator(s) are bullish while THTX’s TA Score has 5 bullish TA indicator(s).

  • SCPH’s TA Score: 5 bullish, 3 bearish.
  • THTX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, SCPH is a better buy in the short-term than THTX.

Price Growth

SCPH (@Biotechnology) experienced а +1.57% price change this week, while THTX (@Biotechnology) price change was +4.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.07%. For the same industry, the average monthly price growth was -6.06%, and the average quarterly price growth was -12.59%.

Reported Earning Dates

SCPH is expected to report earnings on Aug 06, 2025.

THTX is expected to report earnings on Apr 09, 2025.

Industries' Descriptions

@Biotechnology (+7.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SCPH($131M) and THTX($126M) have the same market capitalization . THTX YTD gains are higher at: 48.619 vs. SCPH (-26.836). THTX has higher annual earnings (EBITDA): 10.1M vs. SCPH (-71.31M). SCPH has more cash in the bank: 91.5M vs. THTX (4.34M). THTX (50.4M) and SCPH (52.5M) have identical debt. THTX has higher revenues than SCPH: THTX (88.7M) vs SCPH (30.3M).
SCPHTHTXSCPH / THTX
Capitalization131M126M104%
EBITDA-71.31M10.1M-706%
Gain YTD-26.83648.619-55%
P/E RatioN/AN/A-
Revenue30.3M88.7M34%
Total Cash91.5M4.34M2,108%
Total Debt52.5M50.4M104%
FUNDAMENTALS RATINGS
SCPH vs THTX: Fundamental Ratings
SCPH
THTX
OUTLOOK RATING
1..100
1237
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
8535
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SCPH's Valuation (67) in the Pharmaceuticals Major industry is somewhat better than the same rating for THTX (100) in the null industry. This means that SCPH’s stock grew somewhat faster than THTX’s over the last 12 months.

SCPH's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as THTX (100) in the null industry. This means that SCPH’s stock grew similarly to THTX’s over the last 12 months.

SCPH's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as THTX (100) in the null industry. This means that SCPH’s stock grew similarly to THTX’s over the last 12 months.

THTX's Price Growth Rating (35) in the null industry is somewhat better than the same rating for SCPH (85) in the Pharmaceuticals Major industry. This means that THTX’s stock grew somewhat faster than SCPH’s over the last 12 months.

THTX's P/E Growth Rating (1) in the null industry is significantly better than the same rating for SCPH (100) in the Pharmaceuticals Major industry. This means that THTX’s stock grew significantly faster than SCPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SCPHTHTX
RSI
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
71%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 10 days ago
77%
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 24 days ago
85%
Bearish Trend 8 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Ad is loading...
SCPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
THTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FAOAX33.53N/A
N/A
Fidelity Advisor Overseas A
GSIOX22.96N/A
N/A
Goldman Sachs Small Cap Gr Insghts Instl
AAAZX12.08N/A
N/A
DWS RREEF Real Assets Inst
JACJX15.86N/A
N/A
JHancock Mid Cap Growth A
GMOIX27.63N/A
N/A
GMO International Equity III

SCPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, SCPH has been loosely correlated with BEAM. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if SCPH jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCPH
1D Price
Change %
SCPH100%
-0.77%
BEAM - SCPH
44%
Loosely correlated
+3.87%
ABCL - SCPH
43%
Loosely correlated
+0.79%
XERS - SCPH
42%
Loosely correlated
+0.73%
CRSP - SCPH
41%
Loosely correlated
-1.76%
AURA - SCPH
41%
Loosely correlated
+0.88%
More

THTX and

Correlation & Price change

A.I.dvisor tells us that THTX and SCPH have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that THTX and SCPH's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To THTX
1D Price
Change %
THTX100%
-1.47%
SCPH - THTX
29%
Poorly correlated
-0.77%
IDYA - THTX
27%
Poorly correlated
+0.91%
GNPX - THTX
27%
Poorly correlated
+3.01%
THRD - THTX
26%
Poorly correlated
-0.19%
CSLLY - THTX
26%
Poorly correlated
+0.34%
More